ArticleScientific reports2025
Unraveling the molecular drivers of antibacterial prenylated (iso)flavonoids and chalcones against Streptococcus mutans.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Mycorrhizal Fungal Species Funneliformis mosseae Reshapes Rhizosphere Microbial Metabolic Pathways of Soybeans Under Tetracycline Stress.MicrobiologyOpen · 2026Article
- Identification of Glycosylated and Prenylated (Iso)flavonoids Using cIMS-MS.Analytical chemistry · 2026Article
- Extraction Behavior and Quantitative Profiling of Prenylated Flavonoids from Hops (Molecules (Basel, Switzerland) · 2025Article
- Effective Membrane Permeabilization of Methicillin-ResistantJournal of natural products · 2025Article
- Molecular features of prenylated (iso)flavonoids from Fabaceae in relation to their potential NorA inhibition inFrontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the negative side effects and increased resistance associated with conventional oral antimicrobials, prenylated phenolics are promising alternatives to combat the oral pathogen Streptococcus mutans. A total of 40 prenylated phenolics were evaluated for their antibacterial activity against S. mutans. Eleven prenylated phenolics were purified from licorice (Glycyrrhiza spp.) spent, including the newly discovered double prenylated 2-arylbenzofuran, isokanzonol V. Twenty-eight compounds showed similar potency as chlorhexidine. Activity was correlated with structural properties and novel structure-activity relationships were established: (i) Hydrophobic volume was the main driver associated to activity (double prenylated phenolics were consistently more active than single prenylated phenolics); (ii) the conversion of flavanones to chalcones by C-ring opening increases molecular length and planarity as well as antibacterial activity, and (iii) active single prenylated isoflavones have balanced molecular hydrophilicity. Hence, double or single prenylated phenolics featuring planarity, an extended configuration, and balanced hydrophilicity hold promise for S. mutans control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.